(Q36970128)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Balancing efficacy and safety in treatment with antipsychotics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Christoph U Correll

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

10 Suppl 17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

12-20, 35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

Schizophrenia and increased risks of cardiovascular disease

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Risk of hip fracture in patients with a history of schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Quetiapine in the treatment of rapid cycling bipolar disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effects of newer antipsychotics on extrapyramidal function

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The case for practical clinical trials in psychiatry

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Schizophrenia: a life-shortening disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Early use of clozapine for poorly responding first-episode psychosis.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Clozapine as a first treatment for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Metabolic syndrome in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The role of prolactin in mammary carcinoma

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effectiveness of switching antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Optimal care of patients with type 2 diabetes mellitus and coronary artery disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Quality of medical care and excess mortality in older patients with mental disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Cardiovascular risk factors for people with mental illness

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Atypical antipsychotics and glucose homeostasis.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The association of medical comorbidity in schizophrenia with poor physical and mental health.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Burden of general medical conditions among individuals with bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Determinants of smoking behaviour in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Cigarette smoking among patients with schizophrenia and bipolar disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The distribution of body mass index among individuals with and without schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The metabolic syndrome and schizophrenia: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Medical comorbidity in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Pharmacogenetics of antipsychotic-induced weight gain

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A case series: evaluation of the metabolic safety of aripiprazole

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Obesity as compared with physical activity in predicting risk of coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The primary prevention of coronary heart disease in women

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The primary prevention of myocardial infarction

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Correlates of overweight and obesity in 644 patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

The Relationship between Serum Prolactin Level and Sexual Functioning among Male Outpatients with Schizophrenia or Schizoaffective Disorder: A Randomized Double-Blind Trial of Risperidone vs. Quetiapine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Atypical antipsychotics related metabolic syndrome in bipolar patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Treatment adherence and long-term outcomes.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Real-life switching strategies with second-generation antipsychotics.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900026298

7 January 2021

10.1017/S1092852900026298

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17934385%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference